

Appendix 4E

Preliminary final report

1. Details of reporting period

Name of entity	Cynata Therapeutics Limited (the Company)
ABN	98 104 037 372
Reporting Period	Year ended 30 June 2016
Previous Corresponding Period	Year ended 30 June 2015

2. Results for announcement to the market

Key information	12 months ended 30 June 2016 \$	12 months ended 30 June 2015 \$	Increase/ (decrease) %	Amount change \$
Revenues from ordinary activities	1,247,397	374,889	232.74	872,508
Loss from ordinary activities after tax attributable to members	4,939,471	3,712,077	33.06	1,227,394
Net loss for the period attributable to members	4,939,471	3,712,077	33.06	1,227,394
Net tangible asset/(deficiency) per share	0.063	0.067		

3. Consolidated statement of profit or loss and other comprehensive income

Refer to attached consolidated financial statements.

4. Consolidated statement of financial position

Refer to attached consolidated financial statements.

5. Consolidated statement of cash flows

Refer to attached consolidated financial statements.

6. Consolidated statement of changes in equity

Refer to attached consolidated financial statements.

7. Dividends/Distributions

No dividends declared in current or prior year.

8. Details of dividend reinvestment plans

N/A

9. Details of entities over which control has been gained or lost during the period

N/A

10. Details of associate and joint venture entities

N/A

11. Any other significant information needed by an investor to make an informed assessment of the Company's financial performance and financial position

Refer to attached consolidated financial statements.

12. Foreign entities

Refer to attached consolidated financial statements.

13. Commentary on results for period and explanatory information

Cynata Therapeutics Limited and its controlled entities (the Group) incurred a net loss from operations for the financial year ended 30 June 2016 of \$4,939,471 (2015: \$3,712,077). At 30 June 2016, the Group had a cash balance of \$4,879,173 (2015: \$4,703,689) and net assets of \$8,583,138 (2015: \$8,749,959). The net cash outflow from operating activities for the financial year was \$4,326,353 (2015: \$2,602,346). Substantial progress was made in the Company's product development program during the year. This was particularly recognised in the outcome of the formal Scientific Advice meeting in January with the UK Medicines and Healthcare product Regulatory Agency (MHRA). Several new collaborations were entered into during the year, all of which are intended to expand the profile of the Cymerus™ technology among the international stem cell community and to validate potential clinical applications of therapeutic products deriving from it. The Company successfully completed a capital raising of \$5,000,004 (before costs) via a private placement to institutional investors in the United States of America. The directors believe the Group is in a strong and stable financial position to expand and grow its current operations. For more information, refer to the attached consolidated financial statements.

14. Audit

This report is based on accounts which have been audited and the audit report is included in the attached consolidated financial statements.



Dr. Ross Macdonald
Managing Director

19 August 2016